These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7758056)

  • 21. Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment.
    Sheehan DV; Wright-Etter PJ
    Manag Care Q; 2002; 10(3):21-31. PubMed ID: 12476662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Side effects, dropouts from treatment and cost consequences.
    Montgomery SA; Kasper S
    Int Clin Psychopharmacol; 1998 Feb; 13 Suppl 2():S1-5. PubMed ID: 9669192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoeconomic issues in the treatment of depression.
    Cohen LJ
    Formulary; 1995 Sep; 30 Suppl 1():S20-5. PubMed ID: 10151739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
    Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
    J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.
    Revicki DA; Brown RE; Keller MB; Gonzales J; Culpepper L; Hales RE
    J Clin Psychiatry; 1997 Feb; 58(2):47-58. PubMed ID: 9062373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using pharmacoeconomic data to compare antidepressant therapies.
    Manag Care; 2001 Aug; 10(8 Suppl):14-5; discussion 18-22. PubMed ID: 11729433
    [No Abstract]   [Full Text] [Related]  

  • 27. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoeconomic evaluation of antidepressant therapies.
    Sarnes MW; Frankum LE
    Manag Care; 2004 Jun; 13(6 Suppl Depression):34-41. PubMed ID: 15293769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model.
    Smits KM; Smits LJ; Schouten JS; Peeters FP; Prins MH
    Clin Ther; 2007 Apr; 29(4):691-702. PubMed ID: 17617292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
    Wade AG; Toumi I; Hemels ME
    Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic comparisons of the pharmacotherapy of depression: an overview.
    Crott R; Gilis P
    Acta Psychiatr Scand; 1998 Apr; 97(4):241-52. PubMed ID: 9570483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: a comparative cost-effectiveness approach.
    Béland SG; Tournier M; Galbaud du Fort G; Crott R; Ducruet T; Pariente A; Moride Y
    Value Health; 2011 Jun; 14(4):492-8. PubMed ID: 21669374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of St. John's wort (Hypericum perforatum) for the treatment of mild to moderate depression.
    Solomon D; Adams J; Graves N
    J Affect Disord; 2013 Jun; 148(2-3):228-34. PubMed ID: 23291009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada.
    Lapierre Y; Bentkover J; Schainbaum S; Manners S
    Can J Psychiatry; 1995 Sep; 40(7):370-7. PubMed ID: 8548716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
    Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
    CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system.
    Dunn JD; Cannon E; Mitchell MP; Curtiss FR
    J Manag Care Pharm; 2006 May; 12(4):294-302. PubMed ID: 16792435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
    Anton SF; Revicki DA
    Psychopharmacol Bull; 1995; 31(2):249-58. PubMed ID: 7491376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost analysis of paroxetine versus imipramine in major depression.
    Bentkover JD; Feighner JP
    Pharmacoeconomics; 1995 Sep; 8(3):223-32. PubMed ID: 10155618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.